Buckyballs In The Treatment of Alzheimer's Disease
Buckyball is the first nanoparticle discovered in the year 1985 by the trio scientists Richard Smalley, Harry Kroto, and Robert Curl. Buckyballs also called as fullerene. Fullerene is a powerful antioxidant that reacts with free radicals that cause cell death. Fullerenes and their derivatives have the Antiviral activity to treat the HIV infection. Two of the several brain changes that occur in Alzheimer’s disease are β-amyloid plaques and tau tangles present outside and inside the neurons respectively. The changes in brain, cerebrospinal fluid and blood indicate the earliest sign of Alzheimer's disease (biomarkers) even in the absence of memory loss. Ukrainian scientists discovered Carbon 60 or C-60 or Fullerene or Buckyballs. Through the microinjection C60HyFn (0.46nmol/µl) is injected into the hippocampus. It reduces the deposition of β-amyloid in the pyramidal neurons of hippocampal CA 1 neuron.
2. B.C.Yadav and Ritesh Kumar, InternationalJournal of Nanotechnology and applications 2008; 1(2):15-24.
3. I. Rasovic. Water-soluble Fullerenes for medical applications. Material Sciences and Technology 2017; 33(7), 777-794
4. Ranian Bakry, Rainer M vallant, et al. International Journal of Nanomedicine 2007; 2(4):639-649.
5. Ryan JJ, Bateman HR, Stover A, Gomez G et al. Fullerene nonmaterial inhibit the allergic response. J Immunol 2007; 179(1): 665-72.
6. Seema Thakral, and R.M. Mehta. Fullerenes: An introduction and overview of their biological properties. Indian Journal of Pharmaceutical Sciences 2006; 68(1):13-19.
7. Kroto, H.W; Health, J.R; Brien, S.C; Curl, Smalley, R.E. "C60: Buckminsterfullerene". Nature 1985; 318(6042): 162-163.
8. Smalley, R.E. Discovering the Fullerenes (Nobel lecture). Angewandte Chemie. International Edition in English 1997; 36(15):1594-1661.
9. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid deposition, neurodegenerative and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013; 12 (4):357-67.
10. Jack CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for the sequence of pathological events in Alzheimer's disease. Brain 2009; 132(5): 1355-65.
11. Knopam DS, Parisi JE, Salviati A, Floriach-Robert M et al. Neuropathology of cognitively normal elderly. J Neuropathol EXP. Neurol 2003; 62:1087-95.
12. Roberts R, Knopman DS. Classification epidemiology of MCI. Clin Geriatr Med 2003; 29:753-72.
13. Ward A, Terdiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer's disease to Alzheimer's dementia; A systematic review of the literature. .Demnt Geriatr Cogn Dis Extra 2013; 3:322-32.
14. Walter Derzko. Water-soluble C60 for developing Alzheimer's disease treatment, wired labs, Dec 2, 2013, Available from http://www.wired.com.
15. S.V.Eswaran. Water soluble nanocarbon materials: a panacea for all. Current sciences 2018; 114(9):1846-1850
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).